Dear Dr. Woodcock:

Since we have now surpassed five months since Lotronex has been removed from the
market, our frustration with this issue has increased exponentially.  The only
affective medicine for many of us is not available and, thus, the lack of
availability has caused severe, undue hardship.  To date, the Lotronex Action
Group has yet to receive data from the FDA showing Lotronex causes adverse side
affects more frequently than the average prescription medicine, when properly
prescribed and taken.  Therefore, it is questionable whether the medicine was
removed purely because of data or from perception that the related illness is
not severe enough to warrant the potential for adverse side affects.

As the FDA and GlaxoSmithKline have stated that they understand the severity of
the illness and that talks are currently ongoing, once again, we respectfully
request Lotronex be made available as soon as possible.  It has been five
months.  That is five months that thousands of people have needlessly suffered
from abdominal pain, severe diarrhea, depression, social anxiety and a variety
of other related symptoms.

The Lotronex Action Group has submitted a formal petition to the head of the FDA
and, as of yet, has not heard a response.  It is our hope the FDA and GSK are
working diligently on the resolution of this issue.  The LAG requests that a
schedule be developed, if not already,  with milestone dates established to
nsure progress on the resolution of the issue.  The LAG also requests that this
issue be fast tracked and resolved in the immediate future (ie...one or two
months).  We will be contacting GSK and requesting the same.

Moreover, it is our hope that if and/ or when the medicine is brought back to
the market, it is accessible to those previously taking it without excessive
burden.  As by now, we all know more about this medicine than we ever wanted to.

Sincerely,

The Lotronex Action Group
<lotronexactiongroup@yahoo.com>

Tom Bell, Coordinator
Richard Fireman, Coordinator
Corey Miller, Coordinator

In Partnership with the IBSGroup

Jeffrey Roberts, President